Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan 14;137(2):144-146.
doi: 10.1182/blood.2020009966.

Vaccinations in CLL: implications for COVID-19

Mazyar Shadman  1   2 , Chaitra Ujjani  1   2
Affiliations
Comment

Vaccinations in CLL: implications for COVID-19

Mazyar Shadman et al. Blood. .

Abstract

In this issue of Blood, Pleyer and colleagues report results from 2 studies assessing differences in the humoral response to 2 different vaccines in patients with chronic lymphocytic leukemia (CLL) on observation or receiving a Bruton tyrosine kinase inhibitor (BTKi). Their findings have immediate clinical implications and call for research preparedness as we eagerly anticipate access to vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the near future.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.S. has received consultancy fees, served on advisory boards, steering committees, or data safety monitoring committees for Abbvie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, Verastem, ADC Therapeutics, Beigene, Cellectar, Bristol Myers Squibb, Morphosys, TG Therapeutics, Innate Pharma, and Atara Biotherapeutics, and has received research funding from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, Abbvie, TG Therapeutics, Beigene, AstraZeneca, Sunesis, and Beigene. C.U. has received consultancy fees from Abbvie, Pharmacyclics, AstraZeneca, Gilead/Kite Pharma, Morphosys, Verastem, TG Therapeutics, Epizyme, and Atara and has received research funding from Abbvie, Pharmacyclics, AstraZeneca, Gilead/Kite Pharma, and Loxo Oncology.

Conflict-of-interest disclosure: M.S. has received consultancy fees, served on advisory boards, steering committees, or data safety monitoring committees for Abbvie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, Verastem, ADC Therapeutics, Beigene, Cellectar, Bristol Myers Squibb, Morphosys, TG Therapeutics, Innate Pharma, and Atara Biotherapeutics, and has received research funding from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, Abbvie, TG Therapeutics, Beigene, AstraZeneca, Sunesis, and Beigene. C.U. has received consultancy fees from Abbvie, Pharmacyclics, AstraZeneca, Gilead/Kite Pharma, Morphosys, Verastem, TG Therapeutics, Epizyme, and Atara and has received research funding from Abbvie, Pharmacyclics, AstraZeneca, Gilead/Kite Pharma, and Loxo Oncology.

Figures

None
Variables to consider when studying the efficacy of COVID-19 vaccine in patients with CLL. IVIG, intravenous immunoglobulin.
See this image and copyright information in PMC

Comment on

References

    1. Pleyer C, Ali MA, Cohen JI, et al. . Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185-189. - PMC - PubMed
    1. Sinisalo M, Vilpo J, Itälä M, Väkeväinen M, Taurio J, Aittoniemi J. Efficacy of pneumococcal vaccination on chronic lymphocytic leukemia: should we rely on surrogate markers? Vaccine. 2008;26(32):3959. - PubMed
    1. Iovino L, Shadman M. Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape. Curr Treat Options Oncol. 2020;21(4):24. - PubMed
    1. Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102(10):e397-e399. - PMC - PubMed
    1. Sun C, Gao J, Couzens L, et al. . Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncol. 2016;2(12):1656-1657. - PMC - PubMed